CDK9 and colorectal cancer: The first example of a PROTAC that selectively degrades CDK9 was reported by Rana Sandeep et al., who found that PROTAC 34 (Table 1) degraded CDK9 in a dose-dependent manner in human colorectal cancer cell line HCT116 cells.